Highlights:
ATTRACT trial results a catalyst for advance in management of deep vein thrombosis
SIRT significantly better tolerated than sorafenib, but does not increase overall survival in hepatocellular carcinoma patients
Matthew Callstrom: IO updates
Andrew Holden: PAD trials
Profile: Bob Abraham
[pdfviewer width=”100%” height=”940px” beta=”true”]https://interventionalnews.com/wp-content/uploads/sites/13/2017/05/66-Interventional-News-EU.pdf[/pdfviewer]
